How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,986 results for

Renin-Angiotensin System

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Full Text available with Trip Pro

First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. This is the first update of a Cochrane Review first published in 2015. Renin angiotensin system (RAS) inhibitors include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and renin inhibitors. They are widely prescribed for treatment of hypertension, especially for people with diabetes because of postulated advantages for reducing

2018 Cochrane

2. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Full Text available with Trip Pro

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system improve survival and reduce morbidity in people with heart failure with reduced left ventricular ejection fraction. There is uncertainty whether these treatments are beneficial for people with heart failure with preserved ejection fraction and a comprehensive review of the evidence

2018 Cochrane

3. Renin-angiotensin system drugs

Renin-angiotensin system drugs Renin-angiotensin system drugs: dual ther Renin-angiotensin system drugs: dual therap apy y Key therapeutic topic Published: 15 January 2015 nice.org.uk/guidance/ktt2 pathways Options for local implementation Options for local implementation Dual therapy with an angiotensin-converting enzyme (ACE) inhibitor plus an angiotensin receptor blocker (ARB) has only a limited place in treatment, specifically in a small minority of people with heart failure. Review (...) heart failure and there was an increased risk of hyperkalaemia, hypotension, and impaired renal function. See the NICE medicines evidence commentary Efficacy and safety of dual blockade of the renin-angiotensin system for more information. UK Medicines Information (UKMi) has also published a medicines question and answers resource on the rationale and evidence for combining ACE inhibitors with ARBs for treating hypertension and for preventing vascular events. Dual therapy has only a limited place

2015 National Institute for Health and Clinical Excellence - Advice

4. Early renin?angiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes

Early renin?angiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes Early reninangiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Early reninangiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes Article Text

2017 Evidence-Based Medicine

5. Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease

Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Indranil Dasgupta DM FRCP , Debasish Banerjee MD FRCP , Tahseen A Chowdhury MD FRCP , Parijat De MD FRCP , Mona Wahba MA FRCP , Stephen Bain MD FRCP , Andrew Frankel MD FRCP , Damian Fogarty MD FRCP , Ana Pokrajac (...) MD FRCP and Peter Winocour MD FRCP July 2017 Contents Introduction 3 Evidence grades for the recommendations 3 Search strategy 3 1 Hypertension management and renin-angiotensin-aldosterone system blockade in patients with type 1 diabetes 5 Recommendations 6 Audit standards 6 Areas that require further research 7 Introduction 7 Hypertension in patients with type 1 diabetes 8 Modulation of the RAAS in patients with type 1 diabetes 9 2 Hypertension management and renin-angiotensin-aldosterone system

2017 Association of British Clinical Diabetologists

6. Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia?clarification

Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia?clarification Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 - GOV.UK GOV.UK uses cookies to make the site simpler. Search Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016 In light of feedback, we have clarified (...) our article on concomitant use of these medicines in heart failure. Published 13 December 2016 From: Therapeutic area: , In February 2016, we published an article about the use of spironolactone and renin-angiotensin system drugs in patients with heart failure. Following publication, we received feedback from a small number of readers and a professional organisation that the article was inconsistent with clinical guidelines. We sought advice from the , who considered that the advice outlined

2017 MHRA Drug Safety Update

7. Association of Preoperative Renin-Angiotensin System Inhibitors With Prevention of Postoperative Atrial Fibrillation and Adverse Events: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Association of Preoperative Renin-Angiotensin System Inhibitors With Prevention of Postoperative Atrial Fibrillation and Adverse Events: A Systematic Review and Meta-analysis Postoperative atrial fibrillation (POAF) is a well-known complication after cardiac surgery. Renin-angiotensin system inhibitors (RASIs) have been suggested as an upstream therapy for selected patients with AF; however, evidence in the surgical setting is limited.To evaluate the role of preoperative RASIs in prevention (...) of POAF and adverse events for patients undergoing cardiac surgery.The PubMed database and the Cochrane Library from inception until December 31, 2018, were searched by using the keywords renin-angiotensin system inhibitors OR angiotensin-converting enzyme inhibitors OR angiotensin receptor blocker OR aldosterone antagonist AND cardiac surgery. ClinicalTrials.gov was searched from inception until December 31, 2018, by using the keywords postoperative atrial fibrillation.Randomized clinical trials

2019 EvidenceUpdates

8. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. (Abstract)

First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Renin-angiotensin system (RAS) inhibitors are widely prescribed for treatment of hypertension, especially for diabetic patients on the basis of postulated advantages for the reduction of diabetic nephropathy and cardiovascular morbidity and mortality. Despite widespread use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs

2015 Cochrane

9. Anti-Inflammatory and Antitumor Effects of Hydroxytyrosol but Not Oleuropein on Experimental Glioma In Vivo. A Putative Role for the Renin-Angiotensin System Full Text available with Trip Pro

Anti-Inflammatory and Antitumor Effects of Hydroxytyrosol but Not Oleuropein on Experimental Glioma In Vivo. A Putative Role for the Renin-Angiotensin System Functional roles of the angiotensin peptides of the renin-angiotensin system (RAS) cascade can be analyzed through their corresponding proteolytic regulatory enzymes aspartyl aminopeptidase (ASAP), aminopeptidase A (APA), aminopeptidase B (APB), aminopeptidase N (APN) and insulin-regulated aminopeptidase (IRAP). These enzyme activities

2018 Biomedicines

10. Aerobic exercise training prevents obesity and insulin resistance independent of the renin angiotensin system modulation in the subcutaneous white adipose tissue. Full Text available with Trip Pro

Aerobic exercise training prevents obesity and insulin resistance independent of the renin angiotensin system modulation in the subcutaneous white adipose tissue. We investigate the effects of aerobic exercise training (AET) on the thermogenic response, substrate metabolism and renin angiotensin system (RAS) in the subcutaneous white adipose tissue (SC-WAT) of mice fed cafeteria diet (CAF). Male C57BL/6J mice were assigned into groups CHOW-SED (chow diet, sedentary; n = 10), CHOW-TR (chow diet

2019 PLoS ONE

11. Losartan and isoproterenol promote alterations in the local renin-angiotensin system of rat salivary glands. Full Text available with Trip Pro

Losartan and isoproterenol promote alterations in the local renin-angiotensin system of rat salivary glands. Renin-angiotensin system (RAS) systemically or locally collaborates with tissue homeostasis, growth and development, which has been extensively studied for its pharmacological implications. This study was primarily aimed at finding and characterizing local RAS in rat parotid, sublingual and submandibular glands. It was also hypothesized that vasoactive drugs could affect the expression (...) (ACE and both AT receptors), without affecting morphological alterations, and significantly decreased saliva and total protein secretions. Isoproterenol treatment affected gene expression profiles in parotid (ACE, ACE-2, AT1-a, MAS, AGT), and submandibular (ACE, AT2, AGT) glands, thus promoting acinar hypertrophy in serous acini, without significant changes in salivary flow or total protein content. These drugs affected mainly acini, followed by duct systems and myoepithelial cells, whereas blood

2019 PLoS ONE

12. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study. Full Text available with Trip Pro

Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study. Data on hyperkalemia frequency among chronic kidney disease (CKD) patients receiving renin-angiotensin aldosterone system inhibitors (RAASis) and its impact on subsequent RAASi treatment are limited. This population-based cohort study sought to assess the incidence of clinically significant hyperkalemia among adult CKD patients who were prescribed

2019 PLoS ONE

13. Renin-angiotensin system blockade does not attenuate abdominal aortic aneurysm growth, rupture rate, or perioperative mortality after elective repair Full Text available with Trip Pro

Renin-angiotensin system blockade does not attenuate abdominal aortic aneurysm growth, rupture rate, or perioperative mortality after elective repair The objective of this study was to summarize the literature regarding the effects of renin-angiotensin system blockade (RASB) using angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) on human abdominal aortic aneurysm (AAA) growth, rupture, and perioperative mortality.We conducted a systematic review

2018 EvidenceUpdates

14. Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy Full Text available with Trip Pro

Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy The effect of angiotensin II receptor blockers on right ventricular (RV) function is still unknown. Angiotensin II receptor blockers are beneficial in patients with acquired left ventricular dysfunction, and recent findings have suggested (...) a favorable effect in symptomatic patients with systemic RV dysfunction. The current study aimed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction in adults after repaired tetralogy of Fallot.The REDEFINE trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) is an investigator-initiated, multicenter, prospective, 1:1 randomized, double-blind, placebo-controlled study. Adults with repaired

2018 EvidenceUpdates

15. Budget impact analysis of increasing prescription of renin-angiotensin system inhibitors drugs to standard anti-hypertensive treatments in patients with diabetes and hypertension in a hypothetical cohort of Malaysian population. Full Text available with Trip Pro

Budget impact analysis of increasing prescription of renin-angiotensin system inhibitors drugs to standard anti-hypertensive treatments in patients with diabetes and hypertension in a hypothetical cohort of Malaysian population. Renin-angiotensin system inhibitors (RAS) drugs have a proteinuria-reducing effect that could prevent the progression of kidney disease in diabetic patients. Our study aimed to assess the budget impact based on healthcare payer perspective of increasing uptake of RAS

2019 PLoS ONE

16. The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial Full Text available with Trip Pro

The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear.In a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB

2018 EvidenceUpdates

17. Dynamic Changes in the Renin-Angiotensin-Aldosterone System and the Beneficial Effects of Renin-Angiotensin-Aldosterone Inhibitors on Spatial Learning and Memory in a Rat Model of Chronic Cerebral Ischemia Full Text available with Trip Pro

Dynamic Changes in the Renin-Angiotensin-Aldosterone System and the Beneficial Effects of Renin-Angiotensin-Aldosterone Inhibitors on Spatial Learning and Memory in a Rat Model of Chronic Cerebral Ischemia Renin-angiotensin-aldosterone system (RAAS) plays an important role in the regulation of blood pressure and brain function. Therefore, we studied the dynamic changes in the RAAS in the blood, cerebral cortex, and hippocampus and the effects of RAAS inhibitors on spatial learning and memory (...) and hippocampal apoptosis in a rat model of chronic cerebral ischemia (CCI) established by bilateral ligation of the common carotid arteries of rats. The levels of renin, angiotensin II (Ang II), and aldosterone (ALD) in the plasma, and the homogenates of the left side of cerebral cortex and whole hippocampus of rats were detected on day 1, 3, 7, 14, 21, and 30 by radioimmunoassay. Spatial learning and memory and hippocampal apoptosis were evaluated on day 30 by Morris water maze test (navigation and space

2017 Frontiers in neuroscience

18. Renin-angiotensin-aldosterone system blockers and cardiovascular outcomes: a meta-analysis of randomized clinical trials. Full Text available with Trip Pro

Renin-angiotensin-aldosterone system blockers and cardiovascular outcomes: a meta-analysis of randomized clinical trials. Hypertension is the most prevalent modifiable risk factor for cardiovascular (CV) and cerebrovascular morbidity and mortality. This study aimed to assess the effects of renin-angiotensin-aldosterone system (RAAS) blockade on CV outcomes.This study was designed according to the Preferred Reporting Items for Systemic reviews and Meta-Analyses statement. Databases were searched

2017 Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir

19. Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia

Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article - GOV.UK GOV.UK uses cookies to make the site simpler. Search Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article Monitoring of blood electrolytes is essential in patients (...) that increases sodium excretion while reducing potassium loss at the distal renal tubule. This mechanism of action means that hyperkalaemia can occur, particularly in patients with impaired renal function. Spironolactone should not be used in patients with severe renal impairment or pre-existing hyperkalaemia. Risk of hyperkalaemia with renin-angiotensin system drugs ACEi are mainly indicated in patients with hypertension or heart failure. ARBs are also indicated in hypertension and some are also indicated

2016 MHRA Drug Safety Update

20. Involvement of the renin-angiotensin system in the progression of severe hand-foot-and-mouth disease. Full Text available with Trip Pro

Involvement of the renin-angiotensin system in the progression of severe hand-foot-and-mouth disease. Hand-foot-and-mouth disease (HFMD) is generally considered as a mild exanthematous disease to infants and young children worldwide. HFMD cases are usually mild and self-limiting but for few cases leads to complicated severe clinical outcomes, and even death. Previous studies have indicated that serum Ang II levels in patients with H7N9 infection were related to the severity of infection (...) . However, the mechanisms underlying the pathogenesis of severe HFMD remain unclear. This study was undertaken to clarify the role of the renin-angiotensin system (RAS) in the progression of severe HFMD.In the present study, 162 children including HFMD patients and healthy controls were recruited. The data was analyzed by time-series fashion. Concentrations of angiotensin II (Ang II) and noradrenaline (NA) in serum of patients were measured with ELISA. We established a mouse model for enterovirus 71

2018 PLoS ONE

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>